Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citramel
- Development stage
- Unknown
- Lead developer
- Breathe Easy
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Citramel is an experimental inhaled small molecule therapy developed by Breathe Easy Limited for the treatment of cystic fibrosis (CF). Delivered via nebulizer, Citramel is designed to dissolve the protective biofilms within the thick mucus that accumulates in the lungs of CF patients. By disrupting this biofilm matrix, the drug aims to thin the mucus and enhance the penetration and effectiveness of co-administered antibiotics and the patient's own immune system. Unlike many CF therapies that target the CFTR protein, Citramel targets the physical structure of the mucus/biofilm environment. It has been evaluated in Phase 1/IIa clinical trials for safety and tolerability.
- Brand names
- Citramel
Beyond the preview
Go deeper on Citramel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Citramel.